Communication and information needs of women diagnosed with ovarian cancer regarding treatment-focused genetic testing

Oncology Nursing Forum

Volumn 40, Issue 3, 2013, Pages 275-283

  Gleeson, Margaret ^a,b   Meiser, Bettina ^b,c   Barlow Stewart, Kristine ^d   Trainer, Alison H ^e   Tucker, Kathy ^b   Watts, Kaaren J ^b,f   Friedlander, Michael ^b   Kasparian, Nadine ^g  

^a Hunter Family Cancer Service   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f Psychosocial Research Group   (Australia)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; FEMALE; GENETIC SCREENING; GENETICS; HUMAN; INTERPERSONAL COMMUNICATION; METHODOLOGY; MIDDLE AGED; NEEDS ASSESSMENT; NURSING; ONCOLOGY NURSING; OVARY TUMOR; PATIENT EDUCATION; PATIENT PREFERENCE; PSYCHOLOGICAL ASPECT; QUALITATIVE RESEARCH;

ADULT; AGED; COMMUNICATION; FEMALE; GENETIC TESTING; HUMANS; MIDDLE AGED; NEEDS ASSESSMENT; ONCOLOGY NURSING; OVARIAN NEOPLASMS; PATIENT EDUCATION AS TOPIC; PATIENT PREFERENCE; QUALITATIVE RESEARCH;

EID: 84876912424     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/13.ONF.40-03AP     Document Type: Article

References (33)

1. Alsop, K., Fereday, S., Meldrum, C., DeFazio, A., Emmanuel, C., George, J., . . . Mitchell, G. (2012). BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology, 30, 2654-2663. doi:10.1200/JCO.2011.39.8545
2. Andrews, L., Mireskandari, S., Jessen, J., Thewes, B., Solomon, M., Macrae, F., & Meiser, B. (2006). Impact of familial adenomatous polyposis on young adults: Attitudes to genetic testing, and support and information needs. Genetics in Medicine, 8, 697-703. doi:10.1097/01.gim.0000245574.75877.b9
3. Ardern-Jones, A., Kenen, R., & Eeles, R. (2005). Too much too soon? Patients' and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40. European Journal of Cancer Care, 14, 272-281.
4. Bolton, K., Chenevix-Trench, G., Goh, C., Sadetzki, S., Ramus, S., Karlan, B., . . . Pharoah, P.D. (2012). Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA, 307, 382-390. doi:10.1001/jama.2012.20
5. Bonadona, V., Saltel, P., Desseigne, F., Mignotte, H., Saurin, J.C., Wang, Q., . . . Lasset, C. (2002). Cancer patients who experienced diagnostic genetic testing for cancer susceptibility: Reactions and behavior after the disclosure of a positive test result. Cancer Epidemiology, Biomarkers and Prevention, 11, 97-104.
6. Chetrit, A., Hirsh-Yechezkel, G., Ben-David, Y., Lubin, F., Friedman, E., & Sadetzki, S. (2008). Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: The National Israeli Study of Ovarian Cancer. Journal of Clinical Oncology, 26, 20-25. doi:10.1200/jco.2007.11.6905
7. Chionh, F., Mitchell, G., Lindeman, G.J., Friedlander, M., & Scott, C.L. (2011). The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: Current status and future directions. Asia-Pacific Journal of Clinical Oncology, 7, 197-211. doi:10.1111/j.1743-7563. 2011.01430.x
8. Coffey, A., & Atkinson, P. (1996). Making sense of qualitative data: Complementary research strategies. Thousand Oaks, CA: Sage.
9. Daniels, M.S., Urbauer, D.L., Stanley, J.L., Johnson, K.G., & Lu, K.H. (2009). Timing of BRCA1/BRCA2 genetic testing in women with ovarian cancer. Genetics in Medicine, 11, 624-628. doi:10.1097/GIM.0b013e3181ab2295
10. Denzin, J.M., & Lincoln, Y.S. (1994). Handbook of qualitative research. London, England: Sage.
11. Elit, L., Charles, C., Dimitry, S., Tedford-Gold, S., Gafni, A., Gold, I., & Whelan, T. (2010). It's a choice to move forward: Women's perceptions about treatment decision making in recurrent ovarian cancer. Psycho-Oncology, 19, 318-325. doi:10.1002/pon.1562
12. Fong, P.C., Boss, D.S., Yap, T.A., Tutt, A., Wu, P., Mergui-Roelvink, M., . . . de Bono, J.S. (2009). Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. New England Journal of Medicine, 361, 123-134. doi:10.1056/NEJMoa0900212
13. Fong, P.C., Yap, T.A., Boss, D.S., Carden, C.P., Mergui-Roelvink, M., & Gourley, C. (2010). Poly (ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. Journal of Clinical Oncology, 28, 2512-2519.
14. Foulkes, W.D. (2006). BRCA1 and BRCA2: Chemosensitivity, treatment outcomes, and prognosis. Familial Cancer, 5, 135-142. doi:10.1007/s10689-005- 2832-5
15. Kauff, N.D., Satagopan, J.M., Robson, M.E., Scheuer, L., Hensley, M., Hudis, C.A., . . . Offit, K. (2002). Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. New England Journal of Medicine, 346, 1609-1615.
16. Lacour, R.A., Daniels, M.S., Westin, S.N., Meyer, L.A., Burke, C.C., Burns, K.A., . . . Lu, K.H. (2008). What women with ovarian cancer think and know about genetic testing. Gynecologic Oncology, 111, 132-136. doi:10.1016/j.ygyno.2008.06.016
17. Meiser, B., Gleeson, M., Kasparian, N.A., Barlow-Stewart, K., Ryan, M., & Watts, K. (2012). There is no decision to make: Experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer. Gynecologic Oncology, 124, 153-157.
18. Meiser, B., Mitchell, P., McGirr, H., Van Herten, M., & Schofield, P. (2005). Implications of genetic risk information in families with a high density of bipolar disorder: An exploratory study. Social Science and Medicine, 60, 109-118. doi:10.1016/j.socscimed.2004.04.016
19. Miles, M.B., & Huberman, A.M. (1994). Qualitative data analysis: An expanded sourcebook (2nd ed.). London, England: Sage.
20. Myriad Genetic Laboratories. (2012). BRCA1 and BRCA2 prevalence tables. Retrieved from https://www.myriadpro.com/bracanalysis-prevalence-tables
21. Patton, M. (1980). Qualitative evaluation and research methods (2nd ed.). Newbury Park, CA: Sage.
22. Patton, M. (2002). Qualitative evaluation and research methods (3rd ed.). Thousand Oaks, CA: Sage.
23. Pitman, M.A., & Maxwell, J.A. (1992). Qualitative approaches to evaluation: Models and methods. In M.D. LeCompte, W.L. Millroy, & J. Preissle (Eds.), Handbook of qualitative research in education (pp. 729-770). San Diego, CA: Academic Press.
24. Quinn, J.E., James, C.R., Stewart, G.E., Mulligan, J.M., White, P., Chang, G.K., . . . Harkin, D.P. (2007). BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clinical Cancer Research, 13, 7413-7420.
25. Rebbeck, T.R., Lynch, H.T., Neuhausen, S.L., Narod, S.A., Van't Veer, L., Garber, J.E., . . . Weber, B.L. (2002). Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. New England Journal of Medicine, 346, 1616-1622.
26. Risch, H.A., McLaughlin, J.R., Cole, D.E., Rosen, B., Bradley, L., Kwan, E., . . . Narod, S.A. (2001). Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. American Journal of Human Genetics, 68, 700-710.
27. Schlich-Bakker, K., Ausems, M., Schipper, M., Ten Kroode, H., Warlam-Rodenhuis, C., & van den Bout, J. (2008). BRCA1/2 mutation testing in breast cancer patients: A prospective study of the long-term psychological impact of approach during adjuvant radiotherapy. Breast Cancer Research Treatment, 109, 507-514. doi:10.1007/s10549-007-9680-y
28. Schwartz, M., Lerman, C., Brogan, B., Peshkin, B., Hughes Halbert, C., DeMarco, T., . . . Isaacs, C. (2004). Impact of BRCA1/2 counseling and testing on newly diagnosed breast cancer patients. Journal of Clinical Oncology, 22, 1823-1829. doi:10.1200/JCO.2004.04.086
29. Schwartz, M.D., Lerman, C., Brogan, B., Peshkin, B.N., Isaacs, C., DeMarco, T., . . . Finch, C. (2005). Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiology, Biomarkers and Prevention, 14, 1003-1007. doi:10.1158/1055-9965.EPI-03-0545
30. Tan, D.S., Rothermundt, C., Thomas, K., Bancroft, E., Eeles, R., Shanley, S., . . . Gore, M.E. (2008). "BRCAness" syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. Journal of Clinical Oncology, 26, 5530-5536. doi:10.1200/JCO.2008.16.1703
31. Trainer, A.H., Meiser, B., Watts, K., Mitchell, G., Tucker, K., & Friedlander, M. (2010). Moving toward personalized medicine: Treatment-focused genetic testing of women newly diagnosed with ovarian cancer. International Journal of Gynecological Cancer, 20, 704-716. doi:10.1111/IGC.0b013e3181dbd1a5
32. Vadaparampil, S., Quinn, G., Miree, C., Brzosowicz, J., Carter, B., & Laronga, C. (2009). Recall of and reactions to a surgeon referral letter for BRCA genetic counseling among high-risk breast cancer patients. Annals Surgical Oncology, 16, 1973-1981. doi:10.1245/s10434-009-0479-4
33. van Roosmalen, M.S., Stalmeier, P.F., Verhoef, L.C., Hoekstra-Weebers, J.E., Oosterwijk, J.C., Hoogerbrugge, N., . . . van Daal, W.A.J. (2004). Impact of BRCA1/2 testing and disclosure of a positive test result on women affected and unaffected with breast or ovarian cancer. American Journal of Medical Genetics, Part A, 124, 346-355. doi:10.1002/ajmg.a.20374